-
A Breakthrough for Rare Disease: FDA Approves Joenja for APDS
NASDAQ: $PHAR A New Chapter for Families Affected by APDS In a significant milestone for medical science, the U.S. Food and Drug Administration (FDA) has officially approved Joenja (leniolisib). This approval marks a historic moment as the first-ever treatment specifically indicated for patients 12 years of age and older diagnosed with Activated Phosphoinositide 3-kinase delta…